Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo

BSE1193.7021.2 (+1.81 %)

PREV CLOSE ( ) 1172.50

OPEN PRICE ( ) 1171.95

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 12937

TODAY'S LOW / HIGH ( )1169.65 1199.40

52 WK LOW / HIGH ( )994.35 1364.95

NSE1195.1022.9 (+1.95 %)

PREV CLOSE( ) 1172.20

OPEN PRICE ( ) 1175.10

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 1195.10 (1112)

VOLUME 670100

TODAY'S LOW / HIGH( ) 1170.40 1199.50

52 WK LOW / HIGH ( )1010 1356.2

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 26-12 1986

Management Info

Mangalam Ramasubramanian Kumar - Chairman K Nityananda Reddy - Managing Director

Registered Office

Address Plot No. 2,Maitrivihar ,Ameerpet,
Hyderabad,
Telangana-500038

Phone 040-23736370 / 23747340

Email info@aurobindo.com

Website www.aurobindo.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

02Dec Aurobindo Pharma informs about newspap
Aurobindo Pharma has enclosed the copies of notice published by the Comp..

27Nov Aurobindo Pharma informs about press r
Aurobindo Pharma has informed that it enclosed the copies of notice for..

06Nov Aurobindo Pharma reports marginal rise
Aurobindo Pharma has reported result for second quarter ended September..

30Oct Clarification With Reference To Move
Submission of clarification with reference to movement of volume.

28Oct Aurobindo Pharma informs about earning
Pursuant to Regulation 30(2) of the SEBI (Listing Obligations and Disclo..

Financials

Rs. in Millions

	QTR Sep 25	ANNUAL 25
Net Profit	5813.7	17467.9
Gross Profit	7552.8	23584.5
Operating Profit	8842.2	28856.9
Net Sales	27897.2	109333

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Bharat Parenterals (BSE) 1128.80 (6.39%)	M.Cap ( in Cr)777.96
Amrutanjan Healthcar (BSE) 689.65 (6.38%)	M.Cap ( in Cr)1993.82
Lupin (BSE) 2114.10 (1.62%)	M.Cap ( in Cr)96571.84
Panacea Biotec (BSE) 362.70 (9.53%)	M.Cap ( in Cr)2221.56
Emcure Pharma (BSE) 1439.60 (2.18%)	M.Cap ( in Cr)27289.76

Shareholding Pattern

	PROMOTERS	51.82%
	MUTUAL FUNDS/UTI	19.3%
	NON-INSTITUTION	6.38%
	FI/BANKS/INSURANCE	5.87%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Quant Manufacturing...	8.09
Quant Mid Cap Fund(G)	7.41
Mirae Asset Healthc...	6.67
ICICI Pru Pharma He...	6.06
Quant Large & Mid C...	5.89
Quant Healthcare Fu...	5.80
Tata India Pharma &...	5.44

Risk Disclosures on Derivatives

Smart Quotes

AUROBINDO PHARMA LTD.